Infinity Pharmaceuticals (DB:I3F) - Hisse Senedi Fiyatı, Haberler ve Analizler

I3F Stoklara Genel Bakış

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. Daha fazla detay

I3F temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Risk Analizi

Hisse senetleri oldukça likit değildir

1 yıldan az nakit akışı var

Kazançlar son 5 yılda yılda 14.5% oranında azaldı

Anlamlı bir piyasa değeri yok ( €281K )

+ 2 daha fazla risk

Infinity Pharmaceuticals, Inc. Rakipler

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Paion

DB:PA8K

€44.2k

co.don

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Infinity Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.017
52 Haftanın En Yüksek Seviyesi	US$0.69
52 Haftanın En Düşük Seviyesi	US$0.011
Beta	1.64
11 Aylık Değişim	0%
3 Aylık Değişim	3.64%
1 Yıllık Değişim	-96.42%
33 Yıllık Değişim	-99.01%
5 Yıllık Değişim	-98.15%
Halka arzdan bu yana değişim	-99.40%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	I3F	DE Biotechs	DE Pazar
7D	0%	0.8%	0.8%
1Y	-96.4%	-18.3%	8.6%

Getiri vs. Endüstri: I3F geçen yıl % -18.3 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: I3F geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is I3F's price volatile compared to industry and market?
I3F volatility
I3F Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: I3F hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: I3F 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1995	30	Seth Tasker	www.infi.com

Infinity Pharmaceuticals, Inc. Temel Bilgiler Özeti

Infinity Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
I3F temel i̇stati̇sti̇kler
Piyasa değeri	€256.32k
Kazançlar(TTM)	-€37.30m
Gelir(TTM)	€2.34m

0.1x

P/S Oranı

0.0x

F/K Oranı

I3F aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
I3F gelir tablosu (TTM)
Gelir	US$2.57m
Gelir Maliyeti	US$28.53m
Brüt Kâr	-US$25.96m
Diğer Giderler	US$14.99m
Kazançlar	-US$40.95m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.45
Brüt Marj	-1,010.35%
Net Kâr Marjı	-1,593.93%
Borç/Özkaynak Oranı	0%

I3F uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

I3F Stoklara Genel Bakış

Risk Analizi

Infinity Pharmaceuticals, Inc. Rakipler

HMSE:SBH

€419.8k

BST:BPXA

€772.4k

DB:PA8K

€44.2k

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.50 loss per share (vs US$0.53 loss in FY 2021)

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2021)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2021)

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 1Q 2021)

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings released: US$0.53 loss per share (vs US$0.68 loss in FY 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: €4.00

New 90-day high: €2.00

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

New 90-day high: €1.95

New 90-day high: €1.45

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)

Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

New 90-day high - €1.03

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Infinity Pharmaceuticals, Inc. Temel Bilgiler Özeti

0.1x

0.0x

Kazanç ve Gelir